Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices.

about

Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices.

Item

http://www.wikidata.org/entity/Q38635368

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Rectal protection in prostate ...... o rectal displacement devices.

@en

type

Item

label

Rectal protection in prostate ...... o rectal displacement devices.

@en

prefLabel

Rectal protection in prostate ...... o rectal displacement devices.

@en

P1476

Rectal protection in prostate ...... o rectal displacement devices.

@en

P2093

Jarad Martin

http://www.w3.org/2001/XMLSchema#string

Kimberley Legge

http://www.w3.org/2001/XMLSchema#string

Mark Sidhom

http://www.w3.org/2001/XMLSchema#string

Matthew Richardson

http://www.w3.org/2001/XMLSchema#string

Perry Hunter

http://www.w3.org/2001/XMLSchema#string

Sankar Arumugam

http://www.w3.org/2001/XMLSchema#string

Sarah Keats

http://www.w3.org/2001/XMLSchema#string

Tiffany-Jane Evans

http://www.w3.org/2001/XMLSchema#string

P2860

Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease

Efficacy and safety of argon plasma coagulation for the treatment of hemorrhagic radiation proctitis.

Effects of prostate-rectum separation on rectal dose from external beam radiotherapy.

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR).

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

P304

266-273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMRS.238

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lee Wilton

Mary-Claire Hanlon

P577

2017-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28786219

http://www.w3.org/2001/XMLSchema#string

P932

5715268

http://www.w3.org/2001/XMLSchema#string